This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

GLP-1 Receptor Agonist Market

Market Insights on GLP-1 Receptor Agonist covering sales outlook, demand forecast & up-to-date key trends

GLP-1 Receptor Agonist Market By Route of Administration (Oral, Parenteral), Drug Class (Exenatide, Liraglutide, Dulaglutide, Lixisenatide), Distribution Channel (Hospitals, Clinics, Ambulatory Surgical Centres) & Region - Forecast to 2020-2030

GLP-1 Receptor Agonist Market Findings and Outlook

  • The global GLP-1 Receptor Agonist Market is set to witness steady growth through 2030
  • New product launches remain a key focus area for market players
  • North America and Europe collectively hold more than 70% of market share, with the US holding the lion’s share
  • Covid-19 to stall the market in the short term, with recovery expected in the first quarter of 2021
Customize this Report

Let us know your requirement to get
100% FREE customization

GLP-1 Receptor Agonist Market Snapshot

Globally, nearly 463 Mn people between 20 and 70 years of age are estimated to be suffering from diabetes, as per the International Diabetes Federation in 2019.

Also, as per WHO, over 1.9 Mn adults were found to be overweight as of 2016. Obese and overweight people are at a greater risk of developing cardiovascular and gastric ailments and diabetes.

The GLP-1 receptor agonist market is influenced by an increase in the number of people categorized as obese or diagnosed as diabetics. A growth in these numbers is likely to push adoption of GLP-1 receptor agonists over the forecast period.

New Product Launches Remain Key to Growth

GLP-1 receptor agonist market players are tabling new products to gain a competitive advantage over one another. This trend is bound to drive the market in the forecast period.

For instance –

  • In Jul 2020, 9 Meters Biopharma, started dosing NM-002 (long-acting GLP-1 receptor agonist), which has been designed especially for treating gastric motility by slowing down the digestive transit time
  • In June 2020, Sun Pharmaceuticals announced an updation regarding its pre-clinical module. The experimental NCE (New Chemical Entity) comes across as a long-acting GLP-1R agonist for treating patients suffering from type 2 diabetes inclusive of long-acting, intermediate-acting, and short-acting therapies
  • In Jun 2020, Pfizer showcased Phase I data from study assessing PF-06882961, a GLP-1R agonist in the patients contracting Type 2 Diabetes at the virtual American Diabetes Association meeting. The findings showed that this GLP-1 receptor agonist significantly reduced body weight and glucose levels in these patients
  • In Jun 2020, Novo Nordisk tabled results from a real-world study – “PATHWAY” that extends support to recommendations in clinical guidelines by showcasing that initiating a GLP-1 receptor agonist does help people affected by type 2 diabetes in weight loss as well as reaching blood sugar levels.
  • In Jun 2020, Novo Nordisk announced the approval of Rybelsus (oral semaglutide) (the sole oral GLP-1 R agonist in the form of a tablet) from the Japanese Ministry of Health, Labour and Welfare to treat people with type 2 diabetes
  • In Apr 2020, AstraZeneca funded a clinical trial to evaluate usage of short-acting GLP-1 receptor agonists as one of the add-on treatments to insulin therapy in the type 1 diabetes.
Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

GLP-1 Receptor Agonist Market: R&D Activities

As per researchers at the Icahn School of Medicine, beta cells could be regenerated at much higher rates by combining DYRK1A drugs with GLP-1 receptor agonists.

The GLP-1 receptor agonists could be any of the prescribed meds like Bydureon from AstraZeneca, Trulicity from Eli Lilly, Rybelsus, Ozempic, and Victoria from Novo Nordisk.

“Diabetes Care”, published study results stating that treatment with lixisenatide GLP-1 receptor agonist significantly slows gastric emptying and reduces postprandial glycaemia. In May 2017, “Diabetes, Obesity and Metabolism” published that the ones suffering from type 2 diabetes witnessed lower frequency of gastrointestinal events with a weekly dose of exenatide (a GLP-1 receptor agonist).

“The Lancet Diabetes & Endocrinology”, in Jan 2020, published that GLP-1 receptor agonists could be considered while going for future stroke prevention guidelines for those suffering from diabetes.

Also, in Sep 2019, researchers at the 55th Annual Meeting of the European Association for the Study of Diabetes, reported that a new GLP-1 receptor agonist named “PEX168” showed positive results with respect to treatment of those suffering from type 2 diabetes

Covid-19 Impact on GLP-1 Receptor Agonist Market

The outbreak of Covid-19 has reduced the frequency of research and approvals for GLP-1 receptor agonists This scenario is expected to continue till the end of the year 2020. The normalcy is expected to get restored by the first quarter of the year 2021.

GLP-1 Receptor Agonist Market: Region-wise Analysis

GLP-1 Receptor Agonist Market Download Report Brochure

North America held more than 70% of market share in the year 2019. This could be attributed to the ever-increasing utilization of GLP-1 Receptor Agonists along with a well-established demand-supply chain consisting of pharmaceutical and biopharmaceutical industry.

Europe is the second largest market for GLP-1 receptor agonist, and the growing obesity rates in the region are likely to boost adoption over the forecast period. According to the WHO also states that around 60 million people all across the Europe are suffering from diabetes.

Asia Pacific is expected to grow at the fastest rate in the forecast period due to the fact that more than 70% of the global diabetic population resides in India and China. Also, 40.9% of the population is found to be obese (as per ADB Institute).

GLP-1 Receptor Agonist Market: Competition Landscape

The GLP-1 receptor agonist market players are adopting diverse strategies like geographic expansion and mergers and acquisitions (M&A) for gaining a strong foothold.

For instance – Sanofi, in Jan 2020, made an announcement of acquiring Synthorx, Inc. This acquisition is likely to help the company to lay its hands on genetic alphabet platform technology.

Research collaborations between the players for developing new products have also been moving towards market substantiation.

For instance – Boehringer Ingelheim and Eli Lilly and Company, in Dec 2018, collaborated with DCRI (Duke Clinical Research Institute) to develop GLP-1 Receptor Agonist for addressing cardiovascular ailments and diabetes.

In addition to Eli Lily and Company, and Sanofi, key players in the GLP-1 receptor agonist market include Novo Nordisk and AstraZeneca.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

GLP-1 Receptor Agonist Market: The Way Forward

The GLP-1 Receptor Agonist Market is expected to be going strong, with FMI’s analysis predicting steady growth between 2020 and 2030. Research and innovative approaches are expected to drive the market in the near future.

The key market players need to look upon reaching out to wider geographies through inorganic expansion, so as to cater to a larger patient-base. Innovations are already on the anvil. They, coupled with mergers, acquisitions, partnerships, joint ventures will add to the competitive landscape

Key Segment

Drug Class

  • Exenatide
  • Liraglutide
  • Dulaglutide
  • Lixisenatide
  • Others

Route of Administration

  • Parenteral
  • Oral

Distribution Channel

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centres

Region

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East and Africa

Frequently Asked Questions

The GLP-1 receptor agonist market is likely to secure a CAGR of 10.84% through 2032.

The GLP-1 receptor agonist market size is estimated to cross US$ 11.24 Bn by 2032.

The GLP-1 receptor agonist market is likely to record a value of US$ 4.0169 Bn in 2022.

North America is likely to lead the GLP-1 receptor agonist market.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply Side Trends

    1.4. Drug Class Roadmap

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

    2.3. Inclusions and Exclusions

3. Key Market Trends

    3.1. Key Trends Impacting the Market

    3.2. Development Trends

4. Key Success Factors

    4.1. GLP-1 Receptor Agonist Use Cases

    4.2. Regulatory Landscape

    4.3. Pipeline Assessment

    4.4. Key Promotional Strategies, By Manufacturers

5. Global GLP-1 Receptor Agonist Market Demand (Size in US$ Mn) Analysis 2015-2019 and Forecast, 2020-2030

    5.1. Historical Market Value (US$ Mn) Analysis, 2015-2019

    5.2. Current and Future Market Value (US$ Mn) Projections, 2020-2030

        5.2.1. Y-o-Y Growth Trend Analysis

        5.2.2. Absolute $ Opportunity Analysis

6. Market Background

    6.1. Macro-Economic Factors

        6.1.1. Global GDP Growth Outlook

        6.1.2. Per Capita Healthcare Expenditure Outlook

    6.2. Forecast Factors - Relevance & Impact

        6.2.1. Technology Advancements and Adoptions

        6.2.2. New Product Approvals and Launches

        6.2.3. Rising R & D Funding

        6.2.4. Increasing Incidence and Prevalence of Chronic Diseases

        6.2.5. Regulatory Policies

    6.3. Market Dynamics

        6.3.1. Drivers

        6.3.2. Restraints

        6.3.3. Opportunity Analysis

    6.4. COVID19 Crisis Analysis

        6.4.1. Current COVID19 Statistics and Probable Future Impact

        6.4.2. Current GDP Projection and Probable Impact

        6.4.3. Current Economic Projection as compared to 2008 Economic analysis

        6.4.4. COVID19 and Impact Analysis

            6.4.4.1. Revenue By Drug Class

            6.4.4.2. Revenue By Route of Administration

            6.4.4.3. Revenue By Distribution Channel

            6.4.4.4. Revenue By Country

        6.4.5. 2020 Market Scenario

        6.4.6. Quarter by Quarter Forecast

        6.4.7. Projected recovery Quarter

        6.4.8. Recovery Scenario – Short term, Midterm and Long Term Impact

7. Global GLP-1 Receptor Agonist Market Analysis 2015-2019 and Forecast 2020-2030, by Drug Class

    7.1. Introduction / Key Findings

    7.2. Historical Market Size (US$ Mn) Analysis By Drug Class, 2015–2019

    7.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug Class, 2020-2030

        7.3.1. Exenatide

        7.3.2. Liraglutide

        7.3.3. Dulaglutide

        7.3.4. Lixisenatide

        7.3.5. Others

    7.4. Market Attractiveness Analysis By Drug Class

8. Global GLP-1 Receptor Agonist Market Analysis 2015-2019 and Forecast 2020-2030, by Route of Administration

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2015–2019

    8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Route of Administration, 2020-2030

        8.3.1. Oral

        8.3.2. Parenteral

    8.4. Market Attractiveness Analysis by Route of Administration

9. Global GLP-1 Receptor Agonist Market Analysis 2015-2019 and Forecast 2020-2030, by Distribution Channel

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2015–2019

    9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2020-2030

        9.3.1. Institutional Sales

            9.3.1.1. Hospitals

            9.3.1.2. Clinics

            9.3.1.3. Ambulatory Surgical Centers

        9.3.2. Retail Sales

            9.3.2.1. Hospital Pharmacy

            9.3.2.2. Retail Pharmacy

        9.3.3. Online Sales

    9.4. Market Attractiveness Analysis By Distribution Channel

10. Global GLP-1 Receptor Agonist Market Analysis 2015-2019 and Forecast 2020-2030, by Region

    10.1. Introduction / Key Findings

    10.2. Historical Market Size (US$ Mn) Analysis By Region, 2015–2019

    10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2020-2030

        10.3.1. North America

        10.3.2. Latin America

        10.3.3. Europe

        10.3.4. East Asia

        10.3.5. South Asia

        10.3.6. Oceania

        10.3.7. Middle East and Africa (MEA)

    10.4. Market Attractiveness Analysis By Region

11. North America GLP-1 Receptor Agonist Market Analysis 2015-2019 and Forecast 2020-2030

    11.1. Introduction

    11.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2019

    11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030

        11.3.1.  By Country

            11.3.1.1. U.S.

            11.3.1.2. Canada

        11.3.2. By Drug Class

        11.3.3. By Route of Administration

        11.3.4. By Distribution Channel

    11.4. Market Attractiveness Analysis

        11.4.1. By Country

        11.4.2. By Drug Class

        11.4.3. By Route of Administration

        11.4.4. By Distribution Channel

    11.5. Key Market Participants - Intensity Mapping

    11.6. Drivers and Restraints - Impact Analysis

12. Latin America GLP-1 Receptor Agonist Market Analysis 2015-2019 and Forecast 2020-2030

    12.1. Introduction

    12.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2019

    12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030

        12.3.1.  By Country

            12.3.1.1. Brazil

            12.3.1.2. Mexico

            12.3.1.3. Argentina

            12.3.1.4. Rest of Latin America

        12.3.2. By Drug Class

        12.3.3. Route of Administration

        12.3.4. By Distribution Channel

    12.4. Market Attractiveness Analysis

        12.4.1. By Country

        12.4.2. By Drug Class

        12.4.3. By Route of Administration

        12.4.4. By Distribution Channel

    12.5. Key Market Participants - Intensity Mapping

    12.6. Drivers and Restraints - Impact Analysis

13. Europe GLP-1 Receptor Agonist Market Analysis 2015-2019 and Forecast 2020-2030

    13.1. Introduction

    13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2019

    13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030

        13.3.1.  By Country

            13.3.1.1. Germany

            13.3.1.2. Italy

            13.3.1.3. France

            13.3.1.4. U.K.

            13.3.1.5. Spain

            13.3.1.6. BENELUX

            13.3.1.7. Russia

            13.3.1.8. Rest of Europe

        13.3.2. By Drug Class

        13.3.3. By Route of Administration

        13.3.4. By Distribution Channel

    13.4. Market Attractiveness Analysis

        13.4.1. By Country

        13.4.2. By Drug Class

        13.4.3. By Route of Administration

        13.4.4. By Distribution Channel

    13.5. Key Market Participants - Intensity Mapping

    13.6. Drivers and Restraints - Impact Analysis

14. South Asia GLP-1 Receptor Agonist Market Analysis 2015-2019 and Forecast 2020-2030

    14.1. Introduction

    14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2019

    14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030

        14.3.1.  By Country

            14.3.1.1. India

            14.3.1.2. Thailand

            14.3.1.3. Indonesia

            14.3.1.4. Malaysia

            14.3.1.5. Rest of South Asia

        14.3.2. By Drug Class

        14.3.3. By Route of Administration

        14.3.4. By Distribution Channel

    14.4. Market Attractiveness Analysis

        14.4.1. By Country

        14.4.2. By Drug Class

        14.4.3. By Route of Administration

        14.4.4. By Distribution Channel

    14.5. Key Market Participants - Intensity Mapping

    14.6. Drivers and Restraints - Impact Analysis

15. East Asia GLP-1 Receptor Agonist Market Analysis 2015-2019 and Forecast 2020-2030

    15.1. Introduction

    15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2019

    15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030

        15.3.1.  By Country

            15.3.1.1. China

            15.3.1.2. Japan

            15.3.1.3. South Korea

        15.3.2. By Drug Class

        15.3.3. By Route of Administration

        15.3.4. By Distribution Channel

    15.4. Market Attractiveness Analysis

        15.4.1. By Country

        15.4.2. By Drug Class

        15.4.3. By Route of Administration

        15.4.4. By Distribution Channel

    15.5. Key Market Participants - Intensity Mapping

    15.6. Drivers and Restraints - Impact Analysis

16. Oceania GLP-1 Receptor Agonist Market Analysis 2015-2019 and Forecast 2020-2030

    16.1. Introduction

    16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2019

    16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030

        16.3.1.  By Country

            16.3.1.1. Australia

            16.3.1.2. New Zealand

        16.3.2. By Drug Class

        16.3.3. By Route of Administration

        16.3.4. By Distribution Channel

    16.4. Market Attractiveness Analysis

        16.4.1. By Country

        16.4.2. By Drug Class

        16.4.3. By Route of Administration

        16.4.4. By Distribution Channel

    16.5. Key Market Participants - Intensity Mapping

    16.6. Drivers and Restraints - Impact Analysis

17. Middle East and Africa GLP-1 Receptor Agonist Market Analysis 2015-2019 and Forecast 2020-2030

    17.1. Introduction

    17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2019

    17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030

        17.3.1.  By Country

            17.3.1.1. GCC Countries

            17.3.1.2. Turkey

            17.3.1.3. Northern Africa

            17.3.1.4. South Africa

            17.3.1.5. Rest of Middle East and Africa

        17.3.2. By Drug Class

        17.3.3. By Route of Administration

        17.3.4. By Distribution Channel

    17.4. Market Attractiveness Analysis

        17.4.1. By Country

        17.4.2. By Drug Class

        17.4.3. By Route of Administration

        17.4.4. By Distribution Channel

    17.5. Key Market Participants - Intensity Mapping

    17.6. Drivers and Restraints - Impact Analysis

18. Key and Emerging Countries GLP-1 Receptor Agonist Market Analysis 2015-2019 and Forecast 2020-2030

    18.1. Introduction

        18.1.1. Market Value Proportion Analysis, By Key Countries

        18.1.2. Global Vs. Country Growth Comparison

    18.2. U.S. GLP-1 Receptor Agonist Market Analysis

        18.2.1. By Drug Class

        18.2.2. Route of Administration

        18.2.3. By Distribution Channel

    18.3. Canada GLP-1 Receptor Agonist Market Analysis

        18.3.1. By Drug Class

        18.3.2. Route of Administration

        18.3.3. By Distribution Channel

    18.4. Mexico GLP-1 Receptor Agonist Market Analysis

        18.4.1. By Drug Class

        18.4.2. Route of Administration

        18.4.3. By Distribution Channel

    18.5. Brazil GLP-1 Receptor Agonist Market Analysis

        18.5.1. By Drug Class

        18.5.2. Route of Administration

        18.5.3. By Distribution Channel

    18.6. U.K. GLP-1 Receptor Agonist Market Analysis

        18.6.1. By Drug Class

        18.6.2. Route of Administration

        18.6.3. By Distribution Channel

    18.7. Germany GLP-1 Receptor Agonist Market Analysis

        18.7.1. By Drug Class

        18.7.2. Route of Administration

        18.7.3. By Distribution Channel

    18.8. France GLP-1 Receptor Agonist Market Analysis

        18.8.1. By Drug Class

        18.8.2. Route of Administration

        18.8.3. By Distribution Channel

    18.9. Italy GLP-1 Receptor Agonist Market Analysis

        18.9.1. By Drug Class

        18.9.2. Route of Administration

        18.9.3. By Distribution Channel

    18.10. Spain GLP-1 Receptor Agonist Market Analysis

        18.10.1. By Drug Class

        18.10.2. Route of Administration

        18.10.3. By Distribution Channel

    18.11. BENELUX GLP-1 Receptor Agonist Market Analysis

        18.11.1. By Drug Class

        18.11.2. Route of Administration

        18.11.3. By Distribution Channel

    18.12. Russia GLP-1 Receptor Agonist Market Analysis

        18.12.1. By Drug Class

        18.12.2. Route of Administration

        18.12.3. By Distribution Channel

    18.13. China GLP-1 Receptor Agonist Market Analysis

        18.13.1. By Drug Class

        18.13.2. Route of Administration

        18.13.3. By Distribution Channel

    18.14. Japan GLP-1 Receptor Agonist Market Analysis

        18.14.1. By Drug Class

        18.14.2. Route of Administration

        18.14.3. By Distribution Channel

    18.15. South Korea GLP-1 Receptor Agonist Market Analysis

        18.15.1. By Drug Class

        18.15.2. Route of Administration

        18.15.3. By Distribution Channel

    18.16. India GLP-1 Receptor Agonist Market Analysis

        18.16.1. By Drug Class

        18.16.2. Route of Administration

        18.16.3. By Distribution Channel

    18.17. Australia GLP-1 Receptor Agonist Market Analysis

        18.17.1. By Drug Class

        18.17.2. Route of Administration

        18.17.3. By Distribution Channel

    18.18. New Zealand GLP-1 Receptor Agonist Market Analysis

        18.18.1. By Drug Class

        18.18.2. Route of Administration

        18.18.3. By Distribution Channel

    18.19. GCC Countries GLP-1 Receptor Agonist Market Analysis

        18.19.1. By Drug Class

        18.19.2. Route of Administration

        18.19.3. By Distribution Channel

    18.20. Turkey GLP-1 Receptor Agonist Market Analysis

        18.20.1. By Drug Class

        18.20.2. Route of Administration

        18.20.3. By Distribution Channel

    18.21. South Africa GLP-1 Receptor Agonist Market Analysis

        18.21.1. By Drug Class

        18.21.2. Route of Administration

        18.21.3. By Distribution Channel

19. Market Structure Analysis

    19.1. Market Analysis by Tier of Companies

    19.2. Market Share Analysis of Top Players

    19.3. Company Share Analysis

    19.4. Market Presence Analysis

        19.4.1. By Regional footprint of Players

        19.4.2. Channel Foot Print by Players

20. Competition Analysis

    20.1. Competition Dashboard

    20.2. Competition Benchmarking

    20.3. Competition Deep Dive (Tentative List)

        20.3.1. Eli Lilly and Company

            20.3.1.1. Overview

            20.3.1.2. Service Portfolio

            20.3.1.3. Profitability by Market Segments (Service/Channel/Region)

            20.3.1.4. Sales Footprint

            20.3.1.5. Strategy Overview

                20.3.1.5.1. Marketing Strategy

                20.3.1.5.2. Service Strategy

                20.3.1.5.3. Channel Strategy

        20.3.2. Sanofi

            20.3.2.1. Overview

            20.3.2.2. Service Portfolio

            20.3.2.3. Profitability by Market Segments (Service/Channel/Region)

            20.3.2.4. Sales Footprint

            20.3.2.5. Strategy Overview

                20.3.2.5.1. Marketing Strategy

                20.3.2.5.2. Service Strategy

                20.3.2.5.3. Channel Strategy

        20.3.3. Novo Nordisk A/S

            20.3.3.1. Overview

            20.3.3.2. Service Portfolio

            20.3.3.3. Profitability by Market Segments (Service/Channel/Region)

            20.3.3.4. Sales Footprint

            20.3.3.5. Strategy Overview

                20.3.3.5.1. Marketing Strategy

                20.3.3.5.2. Service Strategy

                20.3.3.5.3. Channel Strategy

        20.3.4. AstraZeneca

            20.3.4.1. Overview

            20.3.4.2. Service Portfolio

            20.3.4.3. Profitability by Market Segments (Service/Channel/Region)

            20.3.4.4. Sales Footprint

            20.3.4.5. Strategy Overview

                20.3.4.5.1. Marketing Strategy

                20.3.4.5.2. Service Strategy

                20.3.4.5.3. Channel Strategy

        20.3.5. Boehringer Ingelheim

            20.3.5.1. Overview

            20.3.5.2. Service Portfolio

            20.3.5.3. Profitability by Market Segments (Service/Channel/Region)

            20.3.5.4. Sales Footprint

            20.3.5.5. Strategy Overview

                20.3.5.5.1. Marketing Strategy

                20.3.5.5.2. Service Strategy

                20.3.5.5.3. Channel Strategy

        20.3.6. Zealand Pharma A/S

            20.3.6.1. Overview

            20.3.6.2. Service Portfolio

            20.3.6.3. Profitability by Market Segments (Service/Channel/Region)

            20.3.6.4. Sales Footprint

            20.3.6.5. Strategy Overview

                20.3.6.5.1. Marketing Strategy

                20.3.6.5.2. Service Strategy

                20.3.6.5.3. Channel Strategy

        20.3.7. HanmiPharm.Co., Ltd

            20.3.7.1. Overview

            20.3.7.2. Service Portfolio

            20.3.7.3. Profitability by Market Segments (Service/Channel/Region)

            20.3.7.4. Sales Footprint

            20.3.7.5. Strategy Overview

                20.3.7.5.1. Marketing Strategy

                20.3.7.5.2. Service Strategy

                20.3.7.5.3. Channel Strategy

        20.3.8. GlaxoSmithKline plc.

            20.3.8.1. Overview

            20.3.8.2. Service Portfolio

            20.3.8.3. Profitability by Market Segments (Service/Channel/Region)

            20.3.8.4. Sales Footprint

            20.3.8.5. Strategy Overview

                20.3.8.5.1. Marketing Strategy

                20.3.8.5.2. Service Strategy

                20.3.8.5.3. Channel Strategy

21. Assumptions and Acronyms Used

22. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 01: Global GLP-1 Receptor Market Analysis 2015-2019 and Forecast 2020–2030, By Drug Class

Table 02: Global GLP-1 Receptor Market Analysis 2015-2019 and Forecast 2020–2030, By Route of Administration

Table 03: Global GLP-1 Receptor Market Analysis 2015-2019 and Forecast 2020–2030, By Distribution Channel

Table 04: Global GLP-1 Receptor Market Analysis 2015-2019 and Forecast 2020–2030, By Region

Table 05: North America GLP-1 Receptor Market Value (US$ Mn) Analysis 2015–2019 and Forecast 2020–2030, By Country

Table 06: North America GLP-1 Receptor Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Drug Class

Table 07: North America GLP-1 Receptor Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Route of Administration

Table 08: North America GLP-1 Receptor Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Distribution Channel

Table 09: Latin America GLP-1 Receptor Market Value (US$ Mn) Analysis 2015–2019 and Forecast 2020–2030, By Country

Table 10: Latin America GLP-1 Receptor Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Drug Class

Table 11: Latin America GLP-1 Receptor Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Route of Administration

Table 12: Latin America GLP-1 Receptor Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Distribution Channel

Table 13: Europe GLP-1 Receptor Market Value (US$ Mn) Analysis 2015–2019 and Forecast 2020–2030, By Country

Table 14: Europe GLP-1 Receptor Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Drug Class

Table 15: Europe GLP-1 Receptor Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Route of Administration

Table 16: Europe GLP-1 Receptor Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Distribution Channel

Table 17: South Asia GLP-1 Receptor Market Value (US$ Mn) Analysis 2015–2019 and Forecast 2020–2030, By Country

Table 18: South Asia GLP-1 Receptor Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Drug Class

Table 19: South Asia GLP-1 Receptor Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Route of Administration

Table 20: South Asia GLP-1 Receptor Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Distribution Channel

Table 21: East Asia GLP-1 Receptor Market Value (US$ Mn) Analysis 2015–2019 and Forecast 2020–2030, By Country

Table 22: East Asia GLP-1 Receptor Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Drug Class

Table 23: East Asia GLP-1 Receptor Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Route of Administration

Table 24: East Asia GLP-1 Receptor Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Distribution Channel

Table 25: Oceania GLP-1 Receptor Market Value (US$ Mn) Analysis 2015–2019 and Forecast 2020–2030, By Country

Table 26: Oceania GLP-1 Receptor Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Drug Class

Table 27: Oceania GLP-1 Receptor Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Route of Administration

Table 28: Oceania GLP-1 Receptor Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Distribution Channel

Table 29: Middle East and Africa GLP-1 Receptor Market Value (US$ Mn) Analysis 2015–2019 and Forecast 2020–2030, By Country

Table 30: Middle East and Africa GLP-1 Receptor Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Drug Class

Table 31: Middle East and Africa GLP-1 Receptor Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Route of Administration

Table 32: Middle East and Africa GLP-1 Receptor Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Distribution Channel

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 01: Global GLP-1 Receptor Market Value Analysis, 2015–2019

Figure 02: Global GLP-1 Receptor Market Forecast & Y-o-Y Growth, 2020–2030

Figure 03: Global GLP-1 Receptor Market Absolute $ Opportunity (US$ Mn) Analysis, 2019–2030

Figure 04: Global GLP-1 Receptor Market Y-o-Y Growth (%) Analysis, 2019–2030

Figure 05: Global GLP-1 Receptor Market Value Share (%) Analysis 2020 & 2030, By Drug Class

Figure 06: Global GLP-1 Receptor Market Y-o-Y Growth (%) Analysis 2019-2030, By Drug Class

Figure 07: Global GLP-1 Receptor Market Attractiveness Analysis 2020–2030, By Drug Class

Figure 08: Global GLP-1 Receptor Market Value Share (%) Analysis 2020 & 2030, By Route of Administration

Figure 09: Global GLP-1 Receptor Market Y-o-Y Growth (%) Analysis 2019-2030, By Route of Administration

Figure 10: Global GLP-1 Receptor Market Attractiveness Analysis 2020–2030, By Route of Administration

Figure 11: Global GLP-1 Receptor Market Value Share (%) Analysis 2020 & 2030, By Distribution Channel

Figure 12: Global GLP-1 Receptor Market Y-o-Y Growth (%) Analysis 2019-2030, By Distribution Channel

Figure 13: Global GLP-1 Receptor Market Attractiveness Analysis 2020–2030, By Distribution Channel

Figure 14: Global GLP-1 Receptor Market Value Share (%) Analysis 2020 & 2030, By Region

Figure 15: Global GLP-1 Receptor Market Y-o-Y Growth (%) Analysis 2019-2030, By Region

Figure 16: Global GLP-1 Receptor Market Attractiveness Analysis 2020–2030, By Region

Figure 17: North America GLP-1 Receptor Market Value Analysis, 2015–2019

Figure 18: North America GLP-1 Receptor Market Forecast & Y-o-Y growth, 2020–2030

Figure 19: North America GLP-1 Receptor Market Attractiveness Analysis, By Drug Class

Figure 20: North America GLP-1 Receptor Market Attractiveness Analysis, By Route of Administration

Figure 21: North America GLP-1 Receptor Market Attractiveness Analysis, By Distribution Channel

Figure 22: North America GLP-1 Receptor Market Attractiveness Analysis, By Country

Figure 23: Latin America GLP-1 Receptor Market Value Analysis, 2015–2019

Figure 24: Latin America GLP-1 Receptor Market Forecast & Y-o-Y growth, 2020–2030

Figure 25: Latin America GLP-1 Receptor Market Attractiveness Analysis, By Drug Class

Figure 26: Latin America GLP-1 Receptor Market Attractiveness Analysis, By Route of Administration

Figure 27: Latin America GLP-1 Receptor Market Attractiveness Analysis, By Distribution Channel

Figure 28: Latin America GLP-1 Receptor Market Attractiveness Analysis, By Country

Figure 29: Europe GLP-1 Receptor Market Value Analysis, 2015–2019

Figure 30: Europe GLP-1 Receptor Market Forecast & Y-o-Y growth, 2020–2030

Figure 31: Europe GLP-1 Receptor Market Attractiveness Analysis, By Drug Class

Figure 32: Europe GLP-1 Receptor Market Attractiveness Analysis, By Route of Administration

Figure 33: Europe GLP-1 Receptor Market Attractiveness Analysis, By Distribution Channel

Figure 34: Europe GLP-1 Receptor Market Attractiveness Analysis, By Country

Figure 35: South Asia GLP-1 Receptor Market Value Analysis, 2015–2019

Figure 36: South Asia GLP-1 Receptor Market Forecast & Y-o-Y growth, 2020–2030

Figure 37: South Asia GLP-1 Receptor Market Attractiveness Analysis, By Drug Class

Figure 38: South Asia GLP-1 Receptor Market Attractiveness Analysis, By Route of Administration

Figure 39: South Asia GLP-1 Receptor Market Attractiveness Analysis, By Distribution Channel

Figure 40: South Asia GLP-1 Receptor Market Attractiveness Analysis, By Country

Figure 41: East Asia GLP-1 Receptor Market Value Analysis, 2015–2019

Figure 42: East Asia GLP-1 Receptor Market Forecast & Y-o-Y growth, 2020–2030

Figure 43: East Asia GLP-1 Receptor Market Attractiveness Analysis, By Drug Class

Figure 44: East Asia GLP-1 Receptor Market Attractiveness Analysis, By Route of Administration

Figure 45: East Asia GLP-1 Receptor Market Attractiveness Analysis, By Distribution Channel

Figure 46: East Asia GLP-1 Receptor Market Attractiveness Analysis, By Country

Figure 47: Oceania GLP-1 Receptor Market Value Analysis, 2015–2019

Figure 48: Oceania GLP-1 Receptor Market Forecast & Y-o-Y growth, 2020–2030

Figure 49: Oceania GLP-1 Receptor Market Attractiveness Analysis, By Drug Class

Figure 50: Oceania GLP-1 Receptor Market Attractiveness Analysis, By Route of Administration

Figure 51: Oceania GLP-1 Receptor Market Attractiveness Analysis, By Distribution Channel

Figure 52: Oceania GLP-1 Receptor Market Attractiveness Analysis, By Country

Figure 53: Middle East and Africa GLP-1 Receptor Market Value Analysis, 2015–2019

Figure 54: Middle East and Africa GLP-1 Receptor Market Forecast & Y-o-Y growth, 2020–2030

Figure 55: Middle East and Africa GLP-1 Receptor Market Attractiveness Analysis, By Drug Class

Figure 56: Middle East and Africa GLP-1 Receptor Market Attractiveness Analysis, By Route of Administration

Figure 57: Middle East and Africa GLP-1 Receptor Market Attractiveness Analysis, By Distribution Channel

Figure 58: Middle East and Africa GLP-1 Receptor Market Attractiveness Analysis, By Country

Figure 59: U.S. GLP-1 Receptor Market Share Analysis (%), 2020E & 2030F

Figure 60: U.S. GLP-1 Receptor Market Share Analysis (%), By Drug Class, 2020E

Figure 61: U.S. GLP-1 Receptor Market Share Analysis (%), By Route of Administration, 2020E

Figure 62: Canada GLP-1 Receptor Market Share Analysis (%), 2020E & 2030F

Figure 63: Canada GLP-1 Receptor Market Share Analysis (%), By Drug Class, 2020E

Figure 64: Canada GLP-1 Receptor Market Share Analysis (%), By Route of Administration, 2020E

Figure 65: Mexico GLP-1 Receptor Market Share Analysis (%), 2020E & 2030F

Figure 66: Mexico GLP-1 Receptor Market Share Analysis (%), By Drug Class, 2020E

Figure 67: Mexico GLP-1 Receptor Market Share Analysis (%), By Route of Administration, 2020E

Figure 68: Brazil GLP-1 Receptor Market Share Analysis (%), 2020E & 2030F

Figure 69: Brazil GLP-1 Receptor Market Share Analysis (%), By Drug Class, 2020E

Figure 70: Brazil GLP-1 Receptor Market Share Analysis (%), By Route of Administration, 2020E

Figure 71: U.K. GLP-1 Receptor Market Share Analysis (%), 2020E & 2030F

Figure 72: U.K. GLP-1 Receptor Market Share Analysis (%), By Drug Class, 2020E

Figure 73: U.K. GLP-1 Receptor Market Share Analysis (%), By Route of Administration, 2020E

Figure 74: Germany GLP-1 Receptor Market Share Analysis (%), 2020E & 2030F

Figure 75: Germany GLP-1 Receptor Market Share Analysis (%), By Drug Class, 2020E

Figure 76: Germany GLP-1 Receptor Market Share Analysis (%), By Route of Administration, 2020E

Figure 77: France GLP-1 Receptor Market Share Analysis (%), 2020E & 2030F

Figure 78: France GLP-1 Receptor Market Share Analysis (%), By Drug Class, 2020E

Figure 79: France GLP-1 Receptor Market Share Analysis (%), By Route of Administration, 2020E

Figure 80: Italy GLP-1 Receptor Market Share Analysis (%), 2020E & 2030F

Figure 81: Italy GLP-1 Receptor Market Share Analysis (%), By Drug Class, 2020E

Figure 82: Italy GLP-1 Receptor Market Share Analysis (%), By Route of Administration, 2020E

Figure 83: Russia GLP-1 Receptor Market Share Analysis (%), 2020E & 2030F

Figure 84: Russia GLP-1 Receptor Market Share Analysis (%), By Drug Class, 2020E

Figure 85: Russia GLP-1 Receptor Market Share Analysis (%), By Route of Administration, 2020E

Figure 86: China GLP-1 Receptor Market Share Analysis (%), 2020E & 2030F

Figure 87: China GLP-1 Receptor Market Share Analysis (%), By Drug Class, 2020E

Figure 88: China GLP-1 Receptor Market Share Analysis (%), By Route of Administration, 2020E

Figure 89: Japan GLP-1 Receptor Market Share Analysis (%), 2020E & 2030F

Figure 90: Japan GLP-1 Receptor Market Share Analysis (%), By Drug Class, 2020E

Figure 91: Japan GLP-1 Receptor Market Share Analysis (%), By Route of Administration, 2020E

Figure 92: South Korea GLP-1 Receptor Market Share Analysis (%), 2020E & 2030F

Figure 93: South Korea GLP-1 Receptor Market Share Analysis (%), By Drug Class, 2020E

Figure 94: South Korea GLP-1 Receptor Market Share Analysis (%), By Route of Administration, 2020E

Figure 95: India GLP-1 Receptor Market Share Analysis (%), 2020E & 2030F

Figure 96: India GLP-1 Receptor Market Share Analysis (%), By Drug Class, 2020E

Figure 97: India GLP-1 Receptor Market Share Analysis (%), By Route of Administration, 2020E

Figure 98: Australia GLP-1 Receptor Market Share Analysis (%), 2020E & 2030F

Figure 99: Australia GLP-1 Receptor Market Share Analysis (%), By Drug Class, 2020E

Figure 100: Australia GLP-1 Receptor Market Share Analysis (%), By Route of Administration, 2020E

Figure 101: New Zealand GLP-1 Receptor Market Share Analysis (%), 2020E & 2030F

Figure 102: New Zealand GLP-1 Receptor Market Share Analysis (%), By Drug Class, 2020E

Figure 103: New Zealand GLP-1 Receptor Market Share Analysis (%), By Route of Administration, 2020E

Figure 104: GCC Countries GLP-1 Receptor Market Share Analysis (%), 2020E & 2030F

Figure 105: GCC Countries GLP-1 Receptor Market Share Analysis (%), By Drug Class, 2020E

Figure 106: GCC Countries GLP-1 Receptor Market Share Analysis (%), By Route of Administration, 2020E

Figure 107: Turkey GLP-1 Receptor Market Share Analysis (%), 2020E & 2030F

Figure 108: Turkey GLP-1 Receptor Market Share Analysis (%), By Drug Class, 2020E

Figure 109: Turkey GLP-1 Receptor Market Share Analysis (%), By Route of Administration, 2020E

Figure 110: South Africa GLP-1 Receptor Market Share Analysis (%), 2020E & 2030F

Figure 111: South Africa GLP-1 Receptor Market Share Analysis (%), By Drug Class, 2020E

Figure 112: South Africa GLP-1 Receptor Market Share Analysis (%), By Route of Administration, 2020E

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports
Google translate

GLP-1 Receptor Agonist Market